Ipsen: Accelerating profitable growth in pharma
Part One: Ipsen, a global pharmaceutical firm headquartered in France, was facing significant challenges, including regulatory setbacks and fierce competition, when David Loew assumed the role of CEO in 2020. The loss of exclusivity for Somatuline, Ipsen’s flagship cancer drug, added to the complexities. Tasked by the board, Loew aimed to lead Ipsen into a new era of profitable growth amid escalating competition. After thorough review during the Covid-19 pandemic, Loew and the executive team recognized the critical importance of the upcoming strategy. Ipsen Investors’ Day became the platform to unveil “Focus. Together. For Patients and Society,” the strategy shaping Ipsen’s trajectory toward ambitious 2025 targets. Despite pandemic disruptions, Loew was confident that Ipsen possessed the essential elements to embark on a new path of profitable growth. Part Two: Three years after launching the new strategy, David Loew concluded a meeting with the head of legal affairs, reflecting on the strategy’s journey. Structured around four pillars, the strategy prioritized patient-centricity, a sustainable pipeline, improved efficiency and operational excellence through collaboration and a diverse workforce. Ipsen’s ambition was to be an adaptable force, creating lasting value. While Ipsen made significant strides in executing the strategy, recognizing market acknowledgment, critical questions persisted. These revolved around geographic footprint, digital integration, ongoing cultural transformation and the accelerated development of key products alongside acquisitions to fortify the pipeline. Loew prepared for a two-day session with the executive team to capitalize on successes and chart the way forward to future-proof the company.
- Understand Ipsen’s strategic transformation: Gain insights into its transformation journey, from its historical roots to its current strategic direction under David Loew’s leadership.
- Understand Ipsen’s competitive environment and the macro factors that have shaped the pharma industry and will influence its future evolution.
- Explore the need for a mid-sized global pharma to design a new strategy in view of likely future disruptions to the sector.
- Explore strategy design in a highly competitive industry.
- Think holistically about how to approach the design of a multi-year corporate strategy.
Ipsen, Healthcare, Biopharmaceuticals, Healthcare, Pharmaceuticals
2019-2024
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Manuel Reman combines Krug’s tradition with innovation, prioritizing authenticity and sustainability to keep the champagne house relevant in evolving times.
Being able to think strategically is key to addressing the ever-increasing demands on leaders – but it's easier said than done. Here are four key capabilities that will help you succeed in turbulent times.
The China Resources Beer (CR Beer) case study is a compelling narrative of the world’s largest beer producer by volume under the leadership of CEO Hou Xiaohai. In 2016 CR Beer embarked on a pivotal transformation journey. This case study offers cr...
Five friends created DIDA in 1983 and turned it into a global provider of IT infrastructure and services. Riding the wave of rapid growth of communication networks and increasingly global business relationships of corporations, DIDA established it...
Honda and Nissan's $58bn merger aims to compete with China's EV dominance, but risks include cultural clashes, overlapping markets, and uncertain innovation outcomes.
Navigate Trump's policy shifts with a clear framework to assess business risks, plan contingencies, and stay ahead in uncertain times. Prepare for what’s next.
Given the world’s many challenges, the ability to forge effective alliances across business, government, the non-profit sector, and academia has become essential to building durable solutions. Here are eight steps to guide you through the process.
Without a robust geopolitical radar, successfully navigating geopolitics is more luck than judgment.
Here are three strategic lessons from the tramp shipping industry.
Why the market for new year predictions is broken and how executives can better use forecasts to discern the implications for their companies.
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 28 January 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
NTT Corporation, Japan’s information and communication technologies (ICT) leader since 1953, was the first to commercialize internet usage on mobile phones in the 1990s, which resulted in NTT achieving much success in Japan. However, by the end of...
Building on NTT (A), the case starts with NTT’s CEO having narrowed down strategic growth options with the board to prepare NTT for the future. Past international investments in AT&T Wireless and KPN to tap into foreign markets had resulted in bil...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications